1.1k citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Carnegie Mellon UniversityUS3 papers
- Eli Lilly (United States)US3 papers
- Harvard UniversityUS3 papers
- New Jersey Institute of TechnologyUS3 papers
- Pfizer (United States)US3 papers
- United States Military AcademyUS3 papers
- University of WashingtonUS3 papers
- Centre National de la Recherche ScientifiqueFR2 papers
- Duke UniversityUS2 papers
- Janssen Research & Development (United States)US2 papers
- Nektar Therapeutics (United States)US2 papers
- New York UniversityUS2 papers
3 papers · 1 filter
Initial recommendations for performing, benchmarking, and reporting single-cell proteomics experiments
Laurent Gatto, Ruedi Aebersold, Juergen Cox +18
Analyzing proteins from single cells by tandem mass spectrometry (MS) has become technically feasible. While such analysis has the potential to accurately quantify thousands of pro…
Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -- Application of the Estimand Framework
Evgeny Degtyarev, Kaspar Rufibach, Yue Shentu +10
COVID-19 outbreak has rapidly evolved into a global pandemic. The impact of COVID-19 on patient journeys in oncology represents a new risk to interpretation of trial results and it…
Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19
Mary Nilsson, Brenda Crowe, Greg Anglin +4
In this paper, we provide guidance on how standard safety analyses and reporting of clinical trial safety data may need to be modified, given the potential impact of the COVID-19 p…